Cosmo: Substantial private placement with Capital Group
Cosmo sold 937,086 treasury shares to Capital Group’s SMALLCAP World Fund, bolstering its balance sheet and diversifying shareholders to fund MedTech AI, dermatology, gastroenterology and CDMO activities; key near-term catalysts are Breezula 12-month safety and efficacy data (spring 2026), Breezula US/EU parallel filings (H1 2026) and Winlevi EU commercial launch (H1 2026).
Why it mattersCapital Group's purchase of 937,086 shares strengthens Cosmo's runway, prompting partners to expedite Breezula regulatory preparations.